A complicated pregnancy in a patient with lipodystrophic diabetes attributable to a peroxisome proliferator-activated receptor gamma (PPARG) mutation

Diabetic Medicine

Volumn 29, Issue 10, 2012, Pages

  Madhra, M ^a   Noh, R M ^a   Zammitt, N N ^a   Patrick, A W ^a   Love, C D B ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CHOLESTEROL; HEMOGLOBIN A1C; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ACUTE PANCREATITIS; ADULT; ARTICLE; CONTINUOUS INFUSION; DIABETES MELLITUS; FEMALE; FETUS LUNG MATURATION; GENE MUTATION; GLYCEMIC CONTROL; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; MALE; PATIENT COMPLIANCE; PLASMAPHERESIS; PREGNANCY COMPLICATION; THIRD TRIMESTER PREGNANCY;

BLOOD GLUCOSE; DEVELOPMENTAL DISABILITIES; DIABETES MELLITUS, TYPE 1; DIET; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; INFANT, NEWBORN; LIPODYSTROPHY; MALE; MUTATION; PANCREATITIS; PATIENT COMPLIANCE; PPAR GAMMA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY IN DIABETICS; PREGNANCY OUTCOME; PREGNANCY, UNPLANNED; YOUNG ADULT;

EID: 84866463833     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03742.x     Document Type: Article

References (18)

1. Agostini M, Schoenmakers E, Mitchell C, Szatmari I, Savage D, Smith A et al. Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance. Cell Metab 2006; 4: 303-311.
2. Hsia SH, Aounelly PW, Hegele RA. Successful outcome in severe pregnancy-associated hyperlipemia: a case report and literature review. Am J Med Sci 1995; 309: 213-218.
3. Swoboda K, Derfler K, Koppensteiner R, Langer M, Pamberger P, Brehm R et al. Extracorporeal lipid elimination for treatment of gestational hyperlipidaemic pancreatitis. Gastroenterology 1993; 104: 1527-1531.
4. Ofori B, Rey E, Bérard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 2007; 64: 496-509.
5. Lehrke M, Lazar MA. The many faces of PPARγ. Cell 2005; 123: 993-999.
6. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of Type2 diabetes. Nat Genetics 2000; 26: 76-80.
7. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
8. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M et al. Human metabolic syndrome resulting from dominant-negative mutations in peroxisome proliferator-activated receptor-γ. Diabetes 2003; 52: 910-917.
9. Catalano PM, Capeless EL, Simmons GM, Robbins DCHorton ES. Successful pregnancy outcome in association with lipoatrophic diabetes mellitus. Obstet Gynecol 1990; 76: 978-979.
10. Demetriou K, Kallikas I, Zouvani I, Kyriacou K, Pierides A. The pregnant patient with partial lipodystrophy developing acute renal failure-onset of de novo membranoproliferative glomerulonephritis. Nephrol Dial Transplant 1998; 13: 2121-2124.
11. Dolberg BK, Lenhard MJ. Successful outcome of pregnancy in a patient with generalized lipoatrophic diabetes mellitus. Endocr Pract 2000; 6: 34-36.
12. Fitch N, Tulandi T. Progressive partial lipodystrophy and third trimester intrauterine fetal death. Am J Obstet Gynecol 1987; 156: 1195-1196.
13. Haxton MJ. Progressive partial lipodystrophy in association with intrauterine death and growth retardation. Am J Obstet Gynecol 1983; 147: 837-838.
14. Morse AN, Whitaker MD. Successful pregnancy in a woman with lipoatrophic diabetes mellitus. A case report. J Reprod Med 2000; 45: 850-852.
15. Vantyghem MC, Vincent-Desplanques F, Defrance-Faivre F, Capeau J, Fermon C, Valag AS et al. Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy. J Clin. Endocrinol Metab 2008; 93: 2223-2229.
16. Lüdtke A, Buettner J, Wu W, Muchir A, Schroeter A, Zinn-Justin S et al. Peroxisome proliferator-activated receptor-γ C190S mutation causes partial lipodystrophy. J Clin Endocrinol Metab 2007; 92: 2248-2255.
17. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P et al. Leptin replacement therapy for lipodystrophy. N Engl J Med 2002; 346: 570-578.
18. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long term efficacy of leptin replacement in patients with generalised lipodystrophy. Diabetes 2005; 54: 1994-2002.